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Abstract
Histone deacetylase inhibitors (HDACIs) have been shown to induce apoptotic and autophagic cell
death in vitro and in vivo. The molecular mechanisms that underlie these cytotoxic effects are not
yet clearly understood. Recently, HDACIs were shown to induce Akt dephosphorylation by
disrupting HDAC-protein phosphatase 1 (PP1) complexes. This disruption results in the increased
association of PP1 with Akt, resulting in the dephosphorylation and consequent inactivation of the
kinase. Akt enhances cellular survival through the phosphorylation-dependent inhibition of several
pro-apoptotic proteins. Akt is an important negative regulator of GSK3β, a kinase that has been
shown to regulate apoptosis in response to various stimuli. In the present study, we investigated
the role of GSK3β in mediating the cytotoxic effects in MCF-7 breast cancer cells treated with
trichostatin A (TSA), a prototype HDACI. We show that TSA induces Akt dephosphorylation in a
PP1-dependent manner, resulting in activation of GSK3β in MCF-7 cells. Similarly, knockdown of
HDAC1 and-2 by small interfering RNA (siRNA) resulted in the dephosphorylation of Akt and
GSK3β. Selective inhibition of GSK3β attenuated TSA induced cytotoxicity and resulted in
enhanced proliferation following drug removal. Our findings identify GSK3β as an important
mediator of TSA-induced cytotoxicity in MCF-7 breast cancer cells.
Findings
Histone deacetylase inhibitors (HDACIs) have been
shown to induce apoptotic and autophagic cell death in
vitro and in vivo [1-3]. The molecular mechanisms that
underlie these cytotoxic effects are not yet clearly under-
stood. Recently, HDACIs were shown to induce Akt (also
called protein kinase B/PKB) dephosphorylation by dis-
rupting HDAC-protein phosphatase 1 (PP1) complexes
[4]. This disruption results in the increased association of
PP1 with Akt, resulting in the dephosphorylation and
consequent inactivation of the kinase. Akt enhances cellu-
lar survival through the phosphorylation-dependent inhi-
bition of several proapoptotic proteins [5-7]. Mutation of
negative regulators of Akt [8] and the deregulated expres-
sion or activation of Akt have been demonstrated in sev-
eral cancers [9]. In addition, Akt activation has been
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shown to be associated with chemoresistance [10]. Phos-
phorylated, active Akt relocalizes to several cellular com-
partments where it phosphorylates a large number of
substrates including FOXO transcription factors, GSK3,
MDM2, BAD, TSC2, p70S6K, ASK1 p21WAF1/Cip1, p27Kip1
and IKKα [6,10]. Akt is an important negative regulator of
GSK3β, a kinase that has been shown to mediate apopto-
sis in response to various stimuli [11-15]. Akt phosphor-
ylates GSK3β on Ser9 and inhibits its activity [16,17].
Recently, GSK3β was shown to be important for mediat-
ing the cell cycle effects of rapamycin and chemosensitiv-
ity to paclitaxel in MCF-7 cells [18]. We have previously
demonstrated a role for GSK3β in mediating the effect of
TSA on cyclin D1 levels in this cell line [19,20]. In the
present study, we investigated the role of GSK3β in medi-
ating cytotoxicity in MCF-7 breast cancer cells treated with
trichostatin A (TSA), a prototype HDACI.
The treatment of U87MG glioblastoma and PC3 prostate
cancer cells with HDAC inhibitors has been shown to
induce the PP1-dependent dephosphorylation of Akt [4].
We investigated the effect of TSA on Akt and GSK3 phos-
phorylation in MCF-7 cells. Culture with 1 μM TSA for 24
h resulted in dephosphorylation of both kinases (Figure
1a). Similar experiments using selective inhibitors of c-Raf
(ZM336372, 1 μM), p38 SAPK (SB203580, 10 μM), Erk1/
2 (PD98059, 20 μM; U0126, 10 μM) and EGFR (genis-
tein, 10 μM) did not result in GSK3β dephosphorylation
(data not shown). In order to verify that Akt inhibition is
sufficient to induce the loss of GSK3β dephosphorylation
on Ser9, MCF-7 cells were treated with a specific Akt
inhibitor. Culture of MCF-7 cells with 50 μM triciribine/
TCN [21] reduced the levels of GSK3β phosphorylation
on Ser9 (see additional file). To determine the role of
phosphatases in mediating Akt and GSK3β dephosphor-
ylation in MCF-7 cells, we investigated the effect of tauto-
mycin and okadaic acid on the phosphorylation of these
kinases. Tautomycin is specific for PP1 while low doses (≤
5 nM) of okadaic acid selectively inhibit PP2A [22,23].
Culture of MCF-7 cells with tautomycin but not low dose
okadaic acid resulted in increased phosphorylation levels
of Akt and GSK3β. Co-culture of MCF-7 cells with TSA and
tautomycin inhibited Akt and GSK3β dephosphorylation
(see additional file 1). Taken together, our findings indi-
cate that TSA induces GSK3β activation by mediating the
PP1-dependent dephosphorylation of Akt in MCF-7 cells.
HDAC inhibitor induced disruption of PP1-HDAC com-
plexes has been linked to protein kinase dephosphoryla-
tion [4]. We investigated the effect of class I HDAC
knockdown by siRNA on protein kinase phosphorylation
in MCF-7 cells. We used commercially available siRNA
oligo pools specifically targeting HDACs 1, 2 and 3 as well
as a non-targeting scrambled control oligo pools. Knock-
down of HDAC1 and to a lesser extent HDAC2 but not
HDAC3 resulted in Akt dephosphorylation. We observed
that the knockdown of HDAC2 resulted in a partial reduc-
tion of HDAC1 levels and this may account for the effect
of HDAC2 siRNA on Akt phosphorylation. Knockdown of
HDAC1 and to a lesser extent HDAC2 and HDAC3 was
sufficient to significantly reduce the phosphorylation lev-
els of GSK3β (Figure 1c) compared with cells transfected
with the non-targeting scrambled control oligos.
Akt facilitates cellular proliferation and survival by nega-
tively regulating several proapoptotic molecules. GSK3β
mediates apoptosis in response to various stimuli and is
inhibited by Akt which phosphorylates the kinase on ser-
ine residue 9. The observation that HDAC inhibition leads
to the dephosphorylation of Akt and GSK3β, suggested
that GSK3β may mediate TSA-induced cytotoxicity in
MCF-7 cells. Specific knockdown of GSK3β by siRNA sig-
nificantly rescued MCF-7 from cell death following treat-
ment with TSA (Figure 1d and 1e). FACS analyses
demonstrated an increase in the S- and G2/M phase pop-
ulation following siRNA mediated GSK3β knockdown in
untreated cells. GSK3β knockdown also resulted in a sig-
nificant decrease in the sub-G1 cell population (~50%)
compared to cells transfected with a non targeting oligo
pool, following treatment with 1 μM TSA for 48 h. GSK3β
knockdown appeared to attenuate the cytotoxic effects of
TSA on cells in the S- and G2/M cell cycle phases [24]
resulting in the increased survival of these populations
(13.8% and 35.0% in S- and G2/M respectively for GSK3β
siRNA transfected cells vs. 6.4% and 23.3% in the control
siRNA transfected population) (Figure 1e). Co-treatment
of MCF-7 cells with TSA and the GSK3β specific inhibitors
SB216763 and lithium chloride (LiCl) also resulted in
enhanced survival compared to cells treated with TSA
alone (Figure 1f and additional file 1). As expected,
SB216763 and LiCl also inhibited tricribine/TCN induced
cytotoxicity (data not shown). Interestingly, LiCl
enhanced the antiproliferative effect of TSA at sub-cyto-
toxic concentrations (<10 nm) but significantly enhanced
survival at concentrations above 10 nM (Figure 1f). These
observations demonstrate that GSK3β is an important
mediator of TSA induced apoptosis in MCF-7 cells and
that inhibition of its activity significantly enhances sur-
vival of these cells following exposure to TSA.
We have shown that TSA induces Akt dephosphorylation
in a PP1-dependent manner, resulting in activation of
GSK3β in MCF-7 cells. Similarly, knockdown of HDAC1
and 2 by small interfering RNA (siRNA) resulted in the
dephosphorylation of Akt and GSK3β. Selective inhibi-
tion of GSK3β attenuated TSA induced cytotoxicity.
HDAC inhibitors have proved promising as anti-cancer
agents in both in vitro and in vivo studies. The precise
mechanisms that underlie their cytostatic and cytotoxic
activities remain poorly defined. Understanding theseMolecular Cancer 2006, 5:40 http://www.molecular-cancer.com/content/5/1/40
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(A). TSA induces Akt and GSK3β dephosphorylation in MCF-7 breast cancer cells Figure 1
(A). TSA induces Akt and GSK3β dephosphorylation in MCF-7 breast cancer cells. MCF-7 cells were incubated with 1 μM TSA 
for the indicated times. Following incubation, the cells were harvested and lysates were resolved by SDS-PAGE. Proteins were 
detected using the indicated antibodies. (B). The relative amounts of pAkt and pGSK3β in A were measured by densitometry 
and normalised to the amount of p38/SAPK. Result is representative of at least three separate experiments. (C). Knockdown 
of class I HDAC proteins induces Akt and GSK3β dephosphorylation. MCF-7 cells were transfected with oligo pools specifi-
cally targeting HDAC1, 2, 3 or a non-targeting siRNA pool (NSC). 72 h after transfection, cells were harvested and lysed. 
Lysates were treated as in A and probed with the indicated antibodies. (D). siRNA-mediated GSK3β knockdown attenuates 
the cytotoxic effect of TSA on MCF-7 cells. MCF-7 cells were transfected with oligo pools specifically targeting GSK3β or a 
non-targeting siRNA pool (NSC). 24 h after transfection cells were harvested and reseeded in 96-well plates and incubated for 
24 h. Cells were then treated with 1 μM TSA for 48 h and relative cell survival was measured as described in materials and 
methods. Results represent the mean ± S.E. from at least three separate experiments. * P < 0.001 TSA treated vs. untreated 
NSC siRNA cells, ** P < 0.001 TSA treated NSC vs. TSA treated GSK3β siRNA cells. Inset: Lysates from cells transfected in 
parallel were probed with antibodies directed against GSK3 to monitor siRNA efficiency. (E). Effect of GSK3β siRNA on TSA 
induced cytotoxicity. Cells were treated as in D and examined by flow cytometry (see materials and methods section). Result 
is representative of at least three separate experiments. (F). Effect of GSK3β inhibition on TSA induced cytotoxicity. MCF-7 
cells were cultured in 96-well plates with 10-9 – 10-5 M TSA alone or in combination with 10 mM LiCl. Relative cell survival was 
determined after 48 h as described in materials and methods section. Result is representative of three separate experiments.
N
S
C
H
D
A
C
1
H
D
A
C
2
H
D
A
C
3
**
*
GSK3
G
S
K
3
β
siRNA:
Actin
N
S
C
NSC GSK3β
- +                     - +
80
40
60
100
20
2.6
57.5
17.9
22.0
16.3
34.9
13.8
35.0
2.5
67.8
11.8
17.9
34,3
34.0
6.4
23.3
Control TSA
G
S
K
3
β
N
S
C
<2N
G1
S
G2/M
<2N
G1
S
G2/M
C
e
l
l
 
 
s
u
r
v
i
v
a
l
 
(
)
A. B.
C.
E.
D.
F.
80
40
60
100
20
P
r
o
t
e
i
n
 
l
e
v
e
l
s
 
(
)
0- 8 -9 -5 -6 -7
0.06
0.08
0.04
0.02
0.12
0.14
0.10
0.16
0.18
C
e
l
l
 
 
s
u
r
v
i
v
a
l
 
(
O
D
 
@
 
4
9
2
 
n
m
)
Log [TSA] M concentration
Control
LiCl
pGSK3β
pAkt
48 12 24 6 0
Time (h)
GSK3β
pGSK3β
pAkt
Akt
HDAC1
HDAC3
HDAC2
Actin
GSK3β
pGSK3β
pAkt
Akt
p38/ SAPK
0       6        12      24      48 h   TSAMolecular Cancer 2006, 5:40 http://www.molecular-cancer.com/content/5/1/40
Page 4 of 6
(page number not for citation purposes)
mechanisms is however important for the design of more
specific HDAC inhibitors. In addition, a better under-
standing of the molecular pharmacology of these inhibi-
tors will aid in the identification of those cancer subtypes
where their application is likely to be most effective from
a clinical standpoint. While GSK3β has been shown to
mediate apoptosis in several cell types, its role in mediat-
ing cytotoxicity in MCF-7 breast cancer cells has only been
recently demonstrated [18]. In that study, GSK3β was
shown to be important for mediating rapamycin-depend-
ent chemosensitization. Furthermore, compounds that
specifically inhibit GSK3β (SB216763, SB415286) were
found to interfere with rapamycin-mediated paclitaxel
sensitization or cell cycle arrest (LiCl). Our findings iden-
tify GSK3β as an important mediator of TSA-induced apo-
potosis in MCF-7 breast cancer cells. Inhibition of GSK3β
with the selective inhibitor SB216763 (as well as LiCl) sig-
nificantly inhibited the cytotoxic effect of TSA on this cell
line. While the use of GSK3β specific inhibitors has not
been linked to the development of cancer, our observa-
tions provide further evidence for the potential of these
compounds to interact negatively with anti-cancer thera-
peutics.
Materials and methods
Reagents
Stock solutions of TSA (Sigma-Aldrich; Dorset, United
Kingdom) in ethanol were stored at -20°C. The GSK3-spe-
cific inhibitor SB216763 (Tocris Bioscience, Avonmouth,
United Kingdom) was dissolved in DMSO and stored at -
20°C. ZM336372, PD98059, SB203580, U0126 and gen-
istein were purchased as 10 mM stock solutions dissolved
in DMSO and stored at -20°C (Tocris bioscience). Lith-
ium Chloride (Sigma-Aldrich) was dissolved in sterile dis-
tilled water and stored at 4°C. The phosphatase inhibitors
okadaic acid and tautomycin (Calbiochem, Beeston, Not-
tingham, United Kingdom) were dissolved in DMSO and
stored at -20°C. Antibodies to actin (Santa Cruz Biotech-
nology, Santa Cruz, CA), phosphor-Akt, Akt,
phosphoGSK3β, GSK3β (Upstate Biotechnology, Dun-
dee, United Kingdom), p38/SAPK (New England Biolabs,
Hitchin, United Kingdom), and HDAC1, HDAC2,
HDAC3 (Abcam, Cambridge, United Kingdom) were
used.
Cell culture and treatments
MCF-7 cells (American Type Culture Collection, Rock-
ville, MD) were cultured in DMEM supplemented with
10% (v/v) fetal calf serum, 2 mM L-glutamine, 100 units/
ml penicillin and 100 μg/ml streptomycin at 37°C in
humidified 5% CO2.
Cell proliferation assay
Cells were seeded in 96-well plates at a predetermined
optimal cell density to ensure exponential growth for
duration of the assay. After a 24 h preincubation, growth
medium was replaced with experimental medium con-
taining the appropriate drug concentrations or 0.1% (v/v)
vehicle control. After a 48 h incubation, cell proliferation
was estimated using the sulforhodamine B colorimetric
assay [25] and expressed as the mean ± SD for six repli-
cates as a percentage of vehicle control (taken as 100%).
Experiments were performed independently at least three
times. Statistical analyses were performed using a two-
tailed Student's t test. P < 0.05 was considered to be statis-
tically significant.
Immunoblotting
Cells treated as indicated were harvested in 5 ml of
medium, pelleted by centrifugation (1,000 × g for 5 min
at 4°C), washed twice with ice-cold PBS and lysed in ice-
cold HEPES buffer [50 mM HEPES (pH 7.5), 10 mM
NaCl, 5 mM MgCl2, 1 mM EDTA, 10% (v/v) glycerol, 1%
(v/v) Triton X-100 and a cocktail of protease inhibitors]
on ice for 30 min. Lysates were clarified by centrifugation
(15,000 × g for 10 min at 4°C) and the supernatants then
either analyzed immediately or stored at -80°C. Equiva-
lent amounts of protein (20–50 μg) from total cell lysates
were resolved by SDS-PAGE using precast 4–12% Bis-Tris
gradient gels (Invitrogen Ltd., Paisley, United Kingdom)
and transferred onto polyvinylidene difluoride (PVDF)
membranes (Hybond P; Amersham Biosciences United
Kingdom Limited, Little Chalfont, United Kingdom) with
a Novex XCell system (Invitrogen). Membranes were
blocked overnight at 4°C in blocking buffer [5% (w/v)
nonfat dried milk, 150 mM NaCl, 10 mM Tris (pH 8.0)
and 0.05% (v/v) Tween 20]. Proteins were detected by
incubation with primary antibodies at appropriate dilu-
tions in blocking buffer overnight at 4°C. Blots were then
incubated at room temperature with horseradish peroxi-
dase-conjugated secondary antibody. Bands were visual-
ized by enhanced chemiluminescence (Supersignal West
Pico; Perbio Science UK Ltd., Cheshire, United Kingdom)
followed by exposure to autoradiography film (Kodak
BioMax ML-light or MR-1). The relative amounts of pro-
tein levels were measured densitometrically using Image
Quant™ software (GE Healthcare UK Ltd., Little Chalford,
United Kingdom) and normalised to the level of p38/
SAPK (loading control).
Flow cytometry
MCF-7 cells were treated as indicated. Floating and adher-
ent cells were collected by centrifugation (500 × g for 5
minutes at 4°C) and washed twice with PBS. Cells were
fixed in 90% ethanol and stored at -20°C. For analysis,
cells were washed in PBS and stained by resuspension in
propidium iodide (PI, 50 μg/mL) in water containing
RNase A (2 μg/mL) for 30 min at 4°C. Single cell suspen-
sions were analysed on a FACScantor cytometer (BD Bio-
sciences Immunocytometry Systems, San Jose, CA). withMolecular Cancer 2006, 5:40 http://www.molecular-cancer.com/content/5/1/40
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CellQuest (BD Biosciences) acquisition software. PI fluo-
rescence was measured through a 585/42 nm band pass
filter, and list mode data were acquired on a minimum of
10,000 single cells defined by a dot blot of PI width versus
PI area.
siRNA transfection
MCF-7 cells were transfected with commercially available
siRNA oligonucleotide pools (Dharmacon, Lafayette, CO)
using Oligofectamine transfection reagent (Invitrogen,
Groningen, The Netherlands) as previously described
[26]. Fugene 6 transfection reagent (Roche Diagnostics
Ltd, East Sussex, United Kingdom) was used for DNA plas-
mid transfection. Asynchronous cell populations at a den-
sity of 50–60% in 6-well plates or on coverslips were
transfected with 1–2 μg of plasmid DNA, following the
formation of lipid-DNA complexes for 20 min at room
temperature in Optimem I medium (Invitrogen). Com-
plexes were added directly to cells growing in 2 ml DMEM
and incubated for 5 h followed by washing with PBS
buffer and addition of fresh DMEM. Cells were normally
used in experiments 24 h following transfection and the
recombinant proteins detected by immunoblotting.
Abbreviations
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Competing interests
The author(s) declare that they have no competing inter-
ests.
Authors' contributions
JPA, DMV, EW-FL and RCC conceived of the study, coor-
dinated its design and execution and drafted the manu-
script. JPA and AVS carried out survival assays, siRNA,
immunoblot experiments and FACS. JPA, AVS and EW-FL
interpreted and analyzed the data. All authors read and
approved the final draft manuscript.
Additional material
Acknowledgements
Grant support was from Association for International Cancer Research and 
the National Translational Cancer Research Network (J.P.A.), The Mandev-
ille Trust (A.V.S.) and Cancer Research UK (E.W-F.L. and R.C.C.). We are 
grateful to David M. Vigushin for his helpful advice.
References
1. Hess-Stumpp H: Histone deacetylase inhibitors and cancer:
from cell biology to the clinic.  Eur J Cell Biol 2005, 84(2-
3):109-121.
2. Minucci S, Pelicci PG: Histone deacetylase inhibitors and the
promise of epigenetic (and more) treatments for cancer.  Nat
Rev Cancer 2006, 6(1):38-51.
3. Shao Y, Gao Z, Marks PA, Jiang X: Apoptotic and autophagic cell
death induced by histone deacetylase inhibitors.  Proc Natl Acad
Sci U S A 2004, 101(52):18030-18035.
4. Chen CS, Weng SC, Tseng PH, Lin HP, Chen CS: Histone acetyla-
tion-independent effect of histone deacetylase inhibitors on
Akt through the reshuffling of protein phosphatase 1 com-
plexes.  J Biol Chem 2005, 280(46):38879-38887.
5. Datta SR, Brunet A, Greenberg ME: Cellular survival: a play in
three Akts.  Genes Dev 1999, 13(22):2905-2927.
6. Shaw RJ, Cantley LC: Ras, PI(3)K and mTOR signalling controls
tumour cell growth.  Nature 2006, 441(7092):424-430.
7. Woodgett JR: Recent advances in the protein kinase B signal-
ing pathway.  Curr Opin Cell Biol 2005, 17(2):150-157.
8. Samuels Y, Diaz LAJ, Schmidt-Kittler O, Cummins JM, Delong L,
Cheong I, Rago C, Huso DL, Lengauer C, Kinzler KW, Vogelstein B,
Velculescu VE: Mutant PIK3CA promotes cell growth and
invasion of human cancer cells.  Cancer Cell 2005, 7(6):561-573.
9. Sun M, Wang G, Paciga JE, Feldman RI, Yuan ZQ, Ma XL, Shelley SA,
Jove R, Tsichlis PN, Nicosia SV, Cheng JQ: AKT1/PKBalpha kinase
is frequently elevated in human cancers and its constitutive
activation is required for oncogenic transformation in
NIH3T3 cells.  Am J Pathol 2001, 159(2):431-437.
Additional file 1
GSK3β mediates TSA-induced cytotoxicity in MCF-7 breast cancer cells. 
Additional file 1 (A). Specific inhibition of Akt is sufficient to induce 
GSK3β dephosphorylation in MCF-7 breast cancer cells. MCF-7 cells 
were incubated with 1 μM TSA or 50 μM triciribine (TCN) for 24 h. Fol-
lowing incubation, the cells were harvested and lysates were resolved by 
SDS-PAGE. Proteins were detected using the indicated antibodies. (B) 
Specific inhibition of protein phosphatase 1 (PP1) enhances Akt and 
GSK3β phosphorylation. MCF-7 cells were incubated for 24 h with 5 μM 
tautomycin, 10 nm okadaic (OA 10) or 100 nm okadaic acid (OA 100). 
Following incubation, the cells were harvested and lysates were resolved by 
SDS-PAGE. Proteins were detected using the indicated antibodies. (C) 
Tautomycin inhibits TSA induced Akt and GSK3β dephosphorylation. 
MCF-7 cells were treated with 1 μM TSA alone or in combination with 5 
μM tautomycin for 24 h. Proteins were detected using the indicated anti-
bodies. (E, F) Specific inhibition of GSK3β attenuates TSA-induced cyto-
toxicity in MCF-7 cells. Cells were treated for 48 h with 1 μM TSA alone 
and in combination with the GSK3β inhibitor SB216763 (5 and 10 μM) 
(SB5, SB10) or 10 mM LiCl. Relative cell survival was measured as 
described in material and methods section. Results represent the mean ± 
S. E. from three separate experiments. *P < 0.05, P < 0.01, TSA treated 
vs. TSA with 5 and 10 μM SB216763 treated cells respectively, P < 
0.0001, TSA treated vs. TSA and LiCl treated cells.
Click here for file
[http://www.biomedcentral.com/content/supplementary/1476-
4598-5-40-S1.ppt]Publish with BioMed Central    and   every 
scientist can read your work free of charge
"BioMed Central will be the most significant development for 
disseminating the results of biomedical research in our lifetime."
Sir Paul Nurse, Cancer Research UK
Your research papers will be:
available free of charge to the entire biomedical community
peer reviewed and published  immediately upon acceptance
cited in PubMed and archived on PubMed Central 
yours — you keep the copyright
Submit your manuscript here:
http://www.biomedcentral.com/info/publishing_adv.asp
BioMedcentral
Molecular Cancer 2006, 5:40 http://www.molecular-cancer.com/content/5/1/40
Page 6 of 6
(page number not for citation purposes)
10. West KA, Castillo SS, Dennis PA: Activation of the PI3K/Akt
pathway and chemotherapeutic resistance.  Drug Resist Updat
2002, 5(6):234-248.
11. Cohen P, Frame S: The renaissance of GSK3.  Nat Rev Mol Cell Biol
2001, 2(10):769-776.
12. Frame S, Cohen P: GSK3 takes centre stage more than 20 years
after its discovery.  Biochem J 2001, 359(Pt 1):1-16.
13. Pastorino JG, Hoek JB, Shulga N: Activation of glycogen synthase
kinase 3beta disrupts the binding of hexokinase II to mito-
chondria by phosphorylating voltage-dependent anion chan-
nel and potentiates chemotherapy-induced cytotoxicity.
Cancer Res 2005, 65(22):10545-10554.
14. Watcharasit P, Bijur GN, Song L, Zhu J, Chen X, Jope RS: Glycogen
synthase kinase-3beta (GSK3beta) binds to and promotes
the actions of p53.  J Biol Chem 2003, 278(49):48872-48879.
15. Yuan J, Zhang J, Wong BW, Si X, Wong J, Yang D, Luo H: Inhibition
of glycogen synthase kinase 3beta suppresses coxsackievirus-
induced cytopathic effect and apoptosis via stabilization of
beta-catenin.  Cell Death Differ 2005, 12(8):1097-1106.
16. Cross DA, Alessi DR, Cohen P, Andjelkovich M, Hemmings BA: Inhi-
bition of glycogen synthase kinase-3 by insulin mediated by
protein kinase B.  Nature 1995, 378(6559):785-789.
17. Cross DA, Watt PW, Shaw M, van der Kaay J, Downes CP, Holder
JC, Cohen P: Insulin activates protein kinase B, inhibits glyco-
gen synthase kinase-3 and activates glycogen synthase by
rapamycin-insensitive pathways in skeletal muscle and adi-
pose tissue.  FEBS Lett 1997, 406(1-2):211-215.
18. Dong J, Peng J, Zhang H, Mondesire WH, Jian W, Mills GB, Hung MC,
Meric-Bernstam F: Role of glycogen synthase kinase 3beta in
rapamycin-mediated cell cycle regulation and chemosensi-
tivity.  Cancer Res 2005, 65(5):1961-1972.
19. Alao JP, Gamble SC, Stavropoulou AV, Pomeranz KM, Lam EW,
Coombes RC, Vigushin DM: The cyclin D1 proto-oncogene is
sequestered in the cytoplasm of mammalian cancer cell
lines.  Mol Cancer 2006, 5:7.
20. Alao JP, Stavropoulou AV, Lam EW, Coombes RC, Vigushin DM: His-
tone deacetylase inhibitor, trichostatin A induces ubiquitin-
dependent cyclin D1 degradation in MCF-7 breast cancer
cells.  Mol Cancer 2006, 5:8.
21. Yang L, Dan HC, Sun M, Liu Q, Sun XM, Feldman RI, Hamilton AD,
Polokoff M, Nicosia SV, Herlyn M, Sebti SM, Cheng JQ: Akt/protein
kinase B signaling inhibitor-2, a selective small molecule
inhibitor of Akt signaling with antitumor activity in cancer
cells overexpressing Akt.  Cancer Res 2004, 64(13):4394-4399.
22. Ivaska J, Nissinen L, Immonen N, Eriksson JE, Kahari VM, Heino J:
Integrin alpha 2 beta 1 promotes activation of protein phos-
phatase 2A and dephosphorylation of Akt and glycogen syn-
thase kinase 3 beta.  Mol Cell Biol 2002, 22(5):1352-1359.
23. Mitsuhashi S, Shima H, Tanuma N, Matsuura N, Takekawa M, Urano
T, Kataoka T, Ubukata M, Kikuchi K: Usage of tautomycetin, a
novel inhibitor of protein phosphatase 1 (PP1), reveals that
PP1 is a positive regulator of Raf-1 in vivo.  J Biol Chem 2003,
278(1):82-88.
24. Qiu L, Burgess A, Fairlie DP, Leonard H, Parsons PG, Gabrielli BG:
Histone deacetylase inhibitors trigger a G2 checkpoint in
normal cells that is defective in tumor cells.  Mol Biol Cell 2000,
11(6):2069-2083.
25. Skehan P, Storeng R, Scudiero D, Monks A, McMahon J, Vistica D,
Warren JT, Bokesch H, Kenney S, Boyd MR: New colorimetric
cytotoxicity assay for anticancer-drug screening.  J Natl Cancer
Inst 1990, 82(13):1107-1112.
26. Alao JP, Lam EW, Ali S, Buluwela L, Bordogna W, Lockey P, Varshochi
R, Stavropoulou AV, Coombes RC, Vigushin DM: Histone deacety-
lase inhibitor trichostatin A represses estrogen receptor
alpha-dependent transcription and promotes proteasomal
degradation of cyclin D1 in human breast carcinoma cell
lines.  Clin Cancer Res 2004, 10(23):8094-8104.